Loading...
T-cell co-stimulation in combination with targeting FAK drives enhanced anti-tumor immunity
Focal Adhesion Kinase (FAK) inhibitors are currently undergoing clinical testing in combination with anti-PD-1 immune checkpoint inhibitors. However, which patients are most likely to benefit from FAK inhibitors, and what the optimal FAK/immunotherapy combinations are, is currently unknown. We ident...
Na minha lista:
| Udgivet i: | eLife |
|---|---|
| Main Authors: | , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
eLife Sciences Publications, Ltd
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6974352/ https://ncbi.nlm.nih.gov/pubmed/31959281 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7554/eLife.48092 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|